Allena Pharmaceuticals, Inc. 5Y Operating CF Growth (per Share)

5Y Operating CF Growth (per Share) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including 5Y Operating CF Growth (per Share) growth rates and interactive chart.


Highlights and Quick Summary

  • Annual 5Y Operating CF Growth (per Share) for 2021 was 0.0% (a NaN% decrease from previous year)
  • Annual 5Y Operating CF Growth (per Share) for 2020 was 0.0% (a NaN% decrease from previous year)
  • Annual 5Y Operating CF Growth (per Share) for 2016 was 0.0% (a NaN% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical 5Y Operating CF Growth (per Share) of Allena Pharmaceuticals, Inc.

Most recent 5Y Operating CF Growth (per Share)of ALNA including historical data for past 10 years.

Interactive Chart of 5Y Operating CF Growth (per Share) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. 5Y Operating CF Growth (per Share) for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.0%
2020 0.0%
2016 0.0%
2015 0.0%

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.